Benzinga · Aug 11, 2026
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
DR
NASDAQ · DRTS
Alpha Tau Medical Ltd.
Healthcare · Biotechnology
$14.92
Up+$0.56 (+3.90%)
Updated Aug 23, 2026, 2:05 AM
SID Score
6.1/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 418.18M
- P/E ratio
- -10.28
- Dividend yield
- 0.00%
- 52-week range
- $6.10 – $15.02
- Volume
- 626.21K
- Avg. volume
- 110.09K
Price performance
DRTS price history
1M range · 20 trading sessions · Daily adjusted prices
DRTS closed at $14.92 after 20 trading sessions, up 22.19% for the selected period.
- Last close
- $14.92
- Period change
- +22.19%
- Period low
- $11.18
- Period high
- $14.92
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 21, 2026 | $14.57 | $15.02 | $14.40 | $14.92 | 626.21K |
| Aug 20, 2026 | $14.47 | $14.60 | $14.20 | $14.36 | 349.16K |
| Aug 19, 2026 | $14.52 | $14.70 | $14.169 | $14.47 | 652K |
| Aug 18, 2026 | $14.00 | $14.57 | $13.77 | $14.26 | 374.76K |
| Aug 17, 2026 | $14.40 | $14.55 | $13.87 | $14.15 | 445.31K |
| Aug 14, 2026 | $14.41 | $14.52 | $14.14 | $14.25 | 314.76K |
| Aug 13, 2026 | $14.37 | $14.75 | $14.0501 | $14.50 | 886.28K |
| Aug 12, 2026 | $14.38 | $14.40 | $13.41 | $13.87 | 500.61K |
| Aug 11, 2026 | $13.43 | $14.30 | $13.31 | $14.27 | 882.98K |
| Aug 10, 2026 | $13.15 | $13.74 | $13.11 | $13.60 | 594.81K |
| Aug 7, 2026 | $13.25 | $13.50 | $13.10 | $13.14 | 297.03K |
| Aug 6, 2026 | $13.31 | $13.55 | $12.795 | $12.99 | 379.65K |
| Aug 5, 2026 | $12.90 | $13.49 | $12.89 | $13.26 | 344.1K |
| Aug 4, 2026 | $12.10 | $13.13 | $12.10 | $13.08 | 582.79K |
| Aug 3, 2026 | $11.69 | $11.94 | $11.40 | $11.92 | 330.49K |
| Jul 31, 2026 | $11.95 | $12.2178 | $11.51 | $11.79 | 272.22K |
| Jul 30, 2026 | $11.41 | $11.95 | $11.30 | $11.89 | 606.28K |
| Jul 29, 2026 | $11.65 | $11.72 | $10.96 | $11.18 | 688.89K |
| Jul 28, 2026 | $12.03 | $12.24 | $11.27 | $11.55 | 909.39K |
| Jul 27, 2026 | $12.96 | $13.09 | $12.14 | $12.21 | 503.97K |
Latest DRTS news
The latest Smart Investors Daily articles mentioning DRTS.
Stock researchCompany · Overview
DRTS research
Overview
Company profile and research snapshot.
Company profile
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $9.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 11, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 22, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 16, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 4, 2026 | HC Wainwright & Co. | Buy | — |
| Jun 4, 2026 | Barclays | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses of $(0.13) per share
Benzinga · Jul 22, 2026
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Yahoo · Jul 21, 2026
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
